United Therapeutics Corporation (UTHR) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $494.63 (-0.53%), Market cap $24.02B, P/E ratio 20.90, 52-week low–high $274.70 ~ $596.76.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ab
Financial statements, price targets, institutional (13F) holdings and related news for United Therapeutics Corporation are updated in real time on BlackAll Trade.
United Therapeutics Corporation trades at $494.63 (-0.53%). Real-time quotes and charts are available on BlackAll Trade.
United Therapeutics Corporation has a market cap of about $24.02B. Its P/E ratio is 20.90.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United Sta